Q-omics provides the consensus-scored C5orf63 profile across patient tissues and cancer cell-line models. C5orf63 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, C5orf63 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, C5orf63 RNA expression shows 18,716 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, THCA, and UVM as cancer lineages where C5orf63 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C5orf63 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C5orf63 survival associations across molecular data types. C5orf63 RNA expression shows survival associations in the most cancer types (28). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C5orf63 RNA expression–survival associations across cancer types. High C5orf63 expression shows unfavorable associations in KICH, OV, LGG, CESC and STAD, but favorable associations in MESO. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for C5orf63 RNA expression.
This table summarizes C5orf63 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C5orf63. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C5orf63 shows lower tumor expression in THCA and KICH and higher tumor expression in BLCA, CHOL, LIHC and UCEC. The THCA box plot shows higher C5orf63 RNA expression in normal versus tumor tissue (log2 FC = −0.874, t-test p < 0.001).
This table shows molecular features associated with C5orf63 in patient tissues and cancer cell lines. In patient samples, C5orf63 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C5orf63 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
